FDA approval of Vera Therapeutics’ Trutakna makes it first in a new class of medicines designed to block two targets to treat immunoglobulin A nephropathy, an autoimmune disease that can progress to end-stage renal failure. Competition looms from Vertex Pharmaceuticals, on track to receive a November regulatory decision for a drug designed to block the same two proteins.
The post Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval appeared first on MedCity News.
Multiple U-Boot Vulnerabilities Enable Pre-Authentication Code Execution and Device DoS Attacks
Six critical vulnerabilities in the widely used U-Boot bootloader, which can be exploited through malicious Flattened Image Tree (FIT) images, allowing attackers to achieve pre-authentication
